Isunakinra

From WikiMD's Wellness Encyclopedia



Isunakinra (also known by its development code EBI-005) is a recombinant protein that acts as an interleukin-1 receptor antagonist. It is being investigated for its potential use in treating inflammatory conditions, particularly those affecting the eyes and skin.

Mechanism of Action[edit | edit source]

Isunakinra functions by inhibiting the activity of interleukin-1 (IL-1), a cytokine that plays a key role in the inflammatory response. By blocking the IL-1 receptor, isunakinra prevents the downstream signaling that leads to inflammation and tissue damage. This mechanism is similar to that of anakinra, another IL-1 receptor antagonist, but isunakinra is engineered to have properties that may be more suitable for topical applications.

Clinical Development[edit | edit source]

Isunakinra has been primarily investigated for the treatment of dry eye disease and allergic conjunctivitis. These conditions are characterized by inflammation of the ocular surface, where IL-1 is thought to be a significant contributor to the pathophysiology.

Dry Eye Disease[edit | edit source]

In clinical trials, isunakinra has been evaluated for its efficacy in reducing the symptoms of dry eye disease, such as ocular discomfort and visual disturbance. The trials have focused on its ability to improve tear production and reduce inflammation on the ocular surface.

Allergic Conjunctivitis[edit | edit source]

For allergic conjunctivitis, isunakinra is being studied for its potential to alleviate symptoms such as itching, redness, and swelling of the eyes. The anti-inflammatory properties of isunakinra may help in reducing the allergic response mediated by IL-1.

Safety and Efficacy[edit | edit source]

The safety profile of isunakinra has been assessed in several clinical trials. Common side effects reported include mild irritation at the site of application. The efficacy results have shown promise, but further studies are needed to confirm its benefits and establish optimal dosing regimens.

Regulatory Status[edit | edit source]

As of the latest updates, isunakinra is still under investigation and has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Also see[edit | edit source]


Template loop detected: Template:Receptor antagonists


Receptor Antagonists
Receptor Type Example Antagonists
Adrenergic receptor Propranolol, Prazosin
Cholinergic receptor Atropine, Scopolamine
Dopamine receptor Haloperidol, Clozapine
Histamine receptor Ranitidine, Diphenhydramine
Serotonin receptor Ondansetron, Risperidone
Glutamate receptor Memantine, Ketamine
GABA receptor Flumazenil, Bicuculline
Opioid receptor Naloxone, Naltrexone
Angiotensin receptor Losartan, Valsartan

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD